Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

"Vascular access complications represent a significant healthcare problem, and we were impressed by the market opportunity for PRT-201 and with the quality of Proteon's team," said Dr. Steven St. Peter, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Proteon."

About PRT-201

PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit www.proteontherapeutics.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tetrachloroethylene (PCE) -- found to have contaminated drinking water ... to 1985 have been linked to certain diseases and ... the National Research Council, Contaminated Water Supplies at Camp ... about the potential adverse health effects that could occur ...
... b3c newswire / - Dutch biotechnology company ... Scientific Research TNO today announced that they have entered ... viral gene delivery platform SVac . Under this agreement, ... and testing of viral gene delivery systems such as ...
... Society for Microbiology (ASM) Siemens Healthcare Diagnostics ... Melissa B. Miller, Ph.D., D(ABMM), director, Clinical ... Pathology and Laboratory Medicine, and associate director, ... North Carolina (UNC) School of Medicine, Chapel ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
... Introducing our Regulatory Edition of Molecular Imaging ... systems for life science research and drug ... compliance with U.S. Food and Drug Administrations ... 11 Electronic Records; Electronic Signatures [21 CFR ...
... for the first time, you can identify ... more efficiently without interferences. The Agilent Multiple ... unwanted, multiple high-abundant proteins from human serum, ... just one device. With this revolutionary system, ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... Kit contains in vitro synthesized, polyadenylated transcripts ... probes on Agilents microarrays, with minimal self- ... positive microarray control in the hybridization protocol. ... a required component of the Agilent One-Color ...
Biology Products: